Farletuzumab ELISA Kit from ABBEXA LTD
Search, find, compare suppliers for Farletuzumab ELISA Kit products.
| Edit | |
|---|---|
| Product Name | Farletuzumab ELISA Kit |
| Description | Farletuzumab ELISA Kit is a quantitative ELISA kit for detection of Farletuzumab. Farletuzumab (MORAb-003) is a humanized ?-FR-targeted monoclonal antibody derived from the murine antibody, LK26 (Teng, Xie, Teng, & Lee, 2012). In preclinical studies, farletuzumab elicited robust antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, thus inhibiting the growth of human ovarian tumor xenografts (Teng et al., 2012). Farletuzumab combined with carboplatin and taxane may enhance the response rate and duration of response in patients with platinum-sensitive ovarian cancer with first relapse after remission duration of 6-18 months (Konner et al., 2010). Based on these encouraging findings, a Phase III study was undertaken in patients with platinum-sensitive recurrent ovarian cancer (Walters et al., 2013). The FAR131 trial did not prove efficacy for patients with platinum-sensitive ovarian cancer (PSOC, defined as a PFI of ? 6 months), in terms of the primary endpoint of PFS. Aside from Farletuzumab, other antibodies have been developed to target FR, and tested clinically. Similar to studies exploiting Vintafolide, a Phase III, open-label, randomized study (ClinicalTrials.gov Identifier: NCT02631876) was designed to compare the safety and efficacy of Mirvetuximab soravtansine, also known as IMGN853, an ?-FR-targeting antibody-drug conjugate, to that of selected single-agent chemotherapies in women with platinum-resistant ?-FR-positive advanced EOC, and other pelvic cancers. The antibody serves to specifically target the highly potent microtubule inhibitor maytansinoid DM4 to the ?-FR-positive cancer cells. In addition, vaccines against FR have been produced and evaluated, such as the folate-binding protein vaccines E39 and J65 involved in the Phase Ib trial (ClinicalTrials.gov Identifier: NCT02019524) for patients with breast or ovarian cancer diagnosis who have been treated and are without evidence of disease. A Phase II clinical trial (NCT02764333) is testing on patients with Pt-resistant ovarian cancer the safety and effectiveness of two investigational drugs, TPIV200/huFR-1 (also called TPIV200), a vaccine consisting of proteins from ?-FR mixed with GM-CSF, and durvalumab (MEDI4736). Range: 0.31 ?g/ml - 5 ?g/ml. Sensitivity: 0.16 ?g/ml |
| Size | 96 tests, |
| Concentration | n/a |
| Applications | ELISA |
| Other Names | Farletuzumab, M3, MORAb-003, MORAb-003-VCP-eribulin, MORAb-202, 896723-44-7, ELISA Farletuzumab, ELISA for Farletuzumab, ELISA kit Farletuzumab, ELISA kit for Farletuzumab, Enzyme-linked immunosorbent assay Farletuzumab, Human Farletuzumab, Farletuzumab ELISA, Farletuzumab ELISA kit, Farletuzumab Enzyme-linked immunosorbent assay, Human Farletuzumab ELISA, Human Farletuzumab ELISA kit, ELISA M3, ELISA for M3, ELISA kit M3, ELISA kit for M3, Enzyme-linked immunosorbent assay M3, Human M3, M3 ELISA, M3 ELISA kit, M3 Enzyme-linked immunosorbent assay, Human M3 ELISA, Human M3 ELISA kit, ELISA MORAb-003, ELISA for MORAb-003, ELISA kit MORAb-003, ELISA kit for MORAb-003, Enzyme-linked immunosorbent assay MORAb-003, Human MORAb-003, MORAb-003 ELISA, MORAb-003 ELISA kit, MORAb-003 Enzyme-linked immunosorbent assay, Human MORAb-003 ELISA, Human MORAb-003 ELISA kit, ELISA MORAb-003-VCP-eribulin, ELISA for MORAb-003-VCP-eribulin, ELISA kit MORAb-003-VCP-eribulin, ELISA kit for MORAb-003-VCP-erib |
| Gene, Accession, CAS # | CAS: 896723-44-7 |
| Catalog # | abx395074 |
| Price | please inquire |
| Order / More Info | Farletuzumab ELISA Kit from ABBEXA LTD |
| Product Specific References | n/a |
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950
Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com
https://www.abbexa.com
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950
Profile of ABBEXA LTD
Return to Products